The historic rise of Viagra has firmly established as a benchmark of pharmaceutical success, however its future within the broader industry now raises questions about future gains. Copycat versions are undercutting exclusivity , causing concerns that betting on companies closely tied to Viagra's previous position could be a dangerous decision , esp